Clene (CLNN) holder SymBiosis II sells 17,909 common shares

Rhea-AI Filing Summary

Clene Inc. disclosed that an entity associated with ten percent owner Ugwumba Chidozie, identified as SymBiosis II, LLC, sold a total of 17,909 shares of Clene common stock in three open-market transactions at prices between $5.40 and $5.78 per share. After these indirect sales, SymBiosis II, LLC continued to hold 532,091 Clene shares.

Insider Trade Summary

Net Seller: 17,909 shares ($99,505)

Net Sell 3 txns

Insider Ugwumba Chidozie

Role 10% Owner

Sold 17,909 shs ($100K)

Type	Security	Shares	Price	Value
Sale	Common Stock	5,319	$5.40	$29K
Sale	Common Stock	7,098	$5.50	$39K
Sale	Common Stock	5,492	$5.78	$32K

Holdings After Transaction: Common Stock — 532,091 shares (Indirect, By SymBiosis II, LLC)

Footnotes (1)

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Ugwumba Chidozie

(Last) (First) (Middle)

609 SW 8TH STREET

SUITE 510

(Street)

BENTONVILLE ARKANSAS 72712

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Clene Inc. [ CLNN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
03/24/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/24/2026		S		5,492	D	$5.78	544,508	I	By SymBiosis II, LLC
Common Stock	03/25/2026		S		7,098	D	$5.5	537,410	I	By SymBiosis II, LLC
Common Stock	03/26/2026		S		5,319	D	$5.4	532,091	I	By SymBiosis II, LLC

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

	/s/ Chidozie Ugwumba	03/26/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider activity did Clene Inc. (CLNN) report in this Form 4?

Clene reported open-market sales of 17,909 common shares by SymBiosis II, LLC, an entity associated with ten percent owner Ugwumba Chidozie. The sales occurred over three days at prices between $5.40 and $5.78 per share.

Who executed the recent Clene (CLNN) share sales disclosed in the Form 4?

The sales were executed by SymBiosis II, LLC, which holds Clene common stock indirectly for ten percent owner Ugwumba Chidozie. All reported transactions involve this entity, not direct personal holdings, according to the ownership description in the filing data.

How many Clene (CLNN) shares were sold and at what prices?

SymBiosis II, LLC sold 17,909 Clene common shares in three open-market transactions. The reported sale prices were $5.78, $5.50, and $5.40 per share on March 24, March 25, and March 26, 2026, respectively.

How many Clene (CLNN) shares does SymBiosis II, LLC hold after these sales?

After the reported transactions, SymBiosis II, LLC holds 532,091 shares of Clene common stock indirectly. This post-transaction balance is shown in the Form 4 as the total shares beneficially owned following the latest sale.

Is the Clene (CLNN) insider a director or officer in this Form 4?

The reporting person, Ugwumba Chidozie, is identified as a ten percent owner but not as a director or officer of Clene. The transactions relate to indirect holdings through SymBiosis II, LLC rather than an executive or board position.

Were there any option exercises or derivative transactions in this Clene (CLNN) Form 4?

No derivative or option exercises were reported. The Form 4 only lists non-derivative common stock sales, and the derivative position summary is empty, indicating no new derivative transactions in this particular filing.